STOCK TITAN

Novavax Inc - NVAX STOCK NEWS

Welcome to our dedicated page for Novavax news (Ticker: NVAX), a resource for investors and traders seeking the latest updates and insights on Novavax stock.

Novavax Inc (NVAX) is a clinical-stage biotechnology company pioneering vaccine development through recombinant nanoparticle technology and its proprietary Matrix-M adjuvant. This dedicated news hub provides investors and industry observers with timely updates on corporate developments, clinical trial progress, and regulatory milestones.

Our curated collection of Novavax news ensures access to official press releases, financial disclosures, and strategic partnership announcements. Users will find updates spanning vaccine candidate advancements, manufacturing expansions, and peer-reviewed research findings. Key content areas include quarterly earnings reports, FDA regulatory submissions, and global health collaborations.

Bookmark this page for streamlined tracking of Novavax's progress in addressing infectious diseases like COVID-19, influenza, and RSV. The resource is regularly updated to serve as your primary source for verified information about NVAX's scientific innovations and market positioning.

Rhea-AI Summary
Novavax grants stock options and restricted stock units to Ian Watkins as inducement for employment
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-12.82%
Tags
none
-
Rhea-AI Summary
Novavax, Inc. will participate in two upcoming investor conferences.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.97%
Tags
conferences
-
Rhea-AI Summary
Novavax's COVID vaccine candidate induces neutralizing responses to emerging subvariants. It could be the only protein-based non-mRNA vaccine option available in key markets for the fall season.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
13.51%
Tags
acquisition covid-19
Rhea-AI Summary
Novavax announces second quarter financial results and operational highlights, including total revenue of $424 million and net income of $58 million. The company has initiated FDA submission for approval of their updated XBB COVID vaccine and plans to be in the market by September. Novavax has also executed a new strategic partnering agreement with SK bioscience, including an equity investment of $85 million. They have reduced their current liabilities by over $1 billion this year and continue to work towards deriving additional value from their pipeline and technology.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.86%
Tags
-
Rhea-AI Summary
Novavax, Inc. will report its second quarter 2023 financial results and operational highlights on August 8, 2023, at 8:30 a.m. EDT. The conference call details and replay information are provided in the press release.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.71%
Tags
conferences earnings
-
Rhea-AI Summary
Novavax has been granted full Marketing Authorization (MA) by the European Commission for Nuvaxovid™ (NVX-CoV2373). The vaccine is authorized for use as a primary series in individuals aged 12 and older and as a booster dose in adults aged 18 and older for the prevention of COVID-19. This MA provides a regulatory foundation for future vaccine updates.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.08%
Tags
covid-19
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.25%
Tags
covid-19
-
Rhea-AI Summary
Novavax, Inc. has adjourned its 2023 Annual Meeting of Stockholders to July 11, 2023. The meeting will be held virtually to vote on proposals described in the Proxy Statement. Proxies representing 49.3% of the shares had been submitted before the adjournment.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.4%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.3%
Tags
conferences
Novavax Inc

Nasdaq:NVAX

NVAX Rankings

NVAX Stock Data

965.07M
146.70M
8.8%
60.18%
24.39%
Biotechnology
Biological Products, (no Disgnostic Substances)
Link
United States
GAITHERSBURG